Parkinson’s Disease and the faecal microbiota transplantation. Review of current knowledge
DOI:
https://doi.org/10.12775/QS.2024.21.54082Keywords
Parkinson's disease, Fecal microbiota transplantation (FMT), brain-gut axisAbstract
Introduction and Purpose.
Parkinson’s Disease (PD) is a chronic neurodegenerative disorder caused by dopamine deficiency due to neuronal degeneration, leading to motor and non-motor symptoms. Gastrointestinal symptoms are common and often precede motor symptoms. There is increasing evidence that imbalanced gut microbiota may influence the gut-brain axis and contribute to motor and non-motor PD symptoms. Fecal microbiota transplantation (FMT) may have the potential to restore gut flora and improve PD symptoms. The study aims to explore the current knowledge on the impact of FMT on PD symptoms, acknowledging existing reviews and highlighting new studies not yet reviewed. Understanding the underlying causes of PD could lead to better treatment, diagnostics, and prevention.
State of knowledge.
PD patients suffer from specific gut dysbiosis which leads to imbalance in the produced pro- and anti-inflammatory substances in the intestinal lumen resulting in aggreviation of α-synuclein in gut nervous cells which may hypothetically transfer via vagal nerve to CNS causing PD. In animal research FMT showed promising results in alleviating PD symptoms. Case reports showed reduction of both motor and non-motor dysfunctions, especially in constipation. DuPont et al. showed improvements in constipation, motor deficits, overall Parkinson’s symptoms, and some non-motor disorders. Cheng et al. showed improvements in MDS-UPDRS, scores of GI tract symptoms scales, PD-related autonomic symptoms and the stool frequency. Bruggeman et al. showed better MDS-UPDRS part 3 scores and better colon transit, but no significant differencies in any other tested domains.
Conclusions.
As there is yet no standarized protocol for FMT, all of the past research used different techniques and showed slightly different outcomes, but all have shown that FMT have some positive effects on PD symptoms.
References
Hayes, M.T. (2019) ‘Parkinson’s disease and parkinsonism’, The American Journal of Medicine, 132(7), pp. 802–807. doi:10.1016/j.amjmed.2019.03.001.
Barone, P. et al. (2009) ‘The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in parkinson’s disease’, Movement Disorders, 24(11), pp. 1641–1649. doi:10.1002/mds.22643.
Pfeiffer, R.F. (2016) ‘Non-motor symptoms in parkinson’s disease’, Parkinsonism & Related Disorders, 22. doi:10.1016/j.parkreldis.2015.09.004.
Tan, A.H. et al. (2020) ‘helicobacter pylori eradication in parkinson’s disease: A randomized placebo‐controlled trial’, Movement Disorders, 35(12), pp. 2250–2260. doi:10.1002/mds.28248.
Lin, C.-H. et al. (2014) ‘Risk of parkinson’s disease following severe constipation: A nationwide population-based cohort study’, Parkinsonism & Related Disorders, 20(12), pp. 1371–1375. doi:10.1016/j.parkreldis.2014.09.026.
Grenham, S. et al. (2011) ‘Brain gut microbe Communication in health and disease’, Frontiers in Physiology, 2. doi:10.3389/fphys.2011.00094.
Mayer, E.A., Tillisch, K. and Gupta, A. (2015) ‘Gut/Brain Axis and the microbiota’, Journal of Clinical Investigation, 125(3), pp. 926–938. doi:10.1172/jci76304.
Rhee, S.H., Pothoulakis, C. and Mayer, E.A. (2009) ‘Principles and clinical implications of the brain–gut–enteric microbiota Axis’, Nature Reviews Gastroenterology & Hepatology, 6(5), pp. 306–314. doi:10.1038/nrgastro.2009.35.
de Vos, W.M. and de Vos, E.A. (2012) ‘Role of the intestinal microbiome in health and disease: From correlation to causation’, Nutrition Reviews, 70. doi:10.1111/j.1753-4887.2012.00505.x.
Braak, H. et al. (2006) ‘Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for parkinson’s disease-related brain pathology’, Neuroscience Letters, 396(1), pp. 67–72. doi:10.1016/j.neulet.2005.11.012.
Desai, M.S. et al. (2016) ‘A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility’, Cell, 167(5). doi:10.1016/j.cell.2016.10.043.
Scheperjans, F. et al. (2014) ‘Gut microbiota are related to parkinson’s disease and clinical phenotype’, Movement Disorders, 30(3), pp. 350–358. doi:10.1002/mds.26069.
Arumugam, M. et al. (2011) ‘Enterotypes of the human gut microbiome’, Nature, 473(7346), pp. 174–180. doi:10.1038/nature09944.
Hirayama, M. and Ohno, K. (2021) ‘Parkinson’s disease and gut microbiota’, Annals of Nutrition and Metabolism, 77(Suppl. 2), pp. 28–35. doi:10.1159/000518147.
Fasano, A. et al. (2015) ‘Gastrointestinal dysfunction in parkinson’s disease’, The Lancet Neurology, 14(6), pp. 625–639. doi:10.1016/s1474-4422(15)00007-1.
Sacino, A.N. et al. (2014) ‘Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in Transgenic Mice’, Proceedings of the National Academy of Sciences, 111(29), pp. 10732–10737. doi:10.1073/pnas.1321785111.
Breen, D.P., Halliday, G.M. and Lang, A.E. (2019) ‘Gut–brain axis and the spread of α‐synuclein pathology: Vagal Highway or dead end?’, Movement Disorders, 34(3), pp. 307–316. doi:10.1002/mds.27556.
Svensson, E. et al. (2015) ‘Vagotomy and subsequent risk of parkinson’s disease’, Annals of Neurology, 78(4), pp. 522–529. doi:10.1002/ana.24448.
Maini Rekdal, V. et al. (2019) ‘Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism’, Science, 364(6445). doi:10.1126/science.aau6323.
van Kessel, S.P. et al. (2019) ‘Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of parkinson’s disease’, Nature Communications, 10(1). doi:10.1038/s41467-019-08294-y.
Xu, M.-Q. (2015) ‘Fecal microbiota transplantation broadening its application beyond intestinal disorders’, World Journal of Gastroenterology, 21(1), p. 102. doi:10.3748/wjg.v21.i1.102.
Song, Y.N. et al. (2021) ‘Fecal microbiota transplantation for severe or fulminant clostridioides difficile infection: Systematic Review and meta-analysis’, Journal of the Canadian Association of Gastroenterology, 5(1). doi:10.1093/jcag/gwab023.
Song, Y. et al. (2013) ‘Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent clostridium difficile infection’, PLoS ONE, 8(11). doi:10.1371/journal.pone.0081330.
Seekatz, A.M. et al. (2014) ‘Recovery of the gut microbiome following fecal microbiota transplantation’, mBio, 5(3). doi:10.1128/mbio.00893-14.
Matheson, J.-A.T. and Holsinger, R.M. (2023) ‘The role of fecal microbiota transplantation in the treatment of Neurodegenerative Diseases: A Review’, International Journal of Molecular Sciences, 24(2), p. 1001. doi:10.3390/ijms24021001.
Sun, M.-F. et al. (2018) ‘Neuroprotective effects of fecal microbiota transplantation on MPTP-induced parkinson’s disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway’, Brain, Behavior, and Immunity, 70, pp. 48–60. doi:10.1016/j.bbi.2018.02.005.
Zhang, T. et al. (2021) ‘Gut microbiota relieves inflammation in the substantia nigra of chronic parkinson’s disease by protecting the function of dopamine neurons’, Experimental and Therapeutic Medicine, 23(1). doi:10.3892/etm.2021.10974.
Sampson, T.R. et al. (2016) ‘Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson’s disease’, Cell, 167(6). doi:10.1016/j.cell.2016.11.018.
Hou, Y. et al. (2021) ‘Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of parkinson’s disease’, Microbiome, 9(1). doi:10.1186/s40168-020-00988-6.
Huang, H. et al. (2019) ‘Fecal microbiota transplantation to treat parkinson’s disease with constipation’, Medicine, 98(26). doi:10.1097/md.0000000000016163.
Segal, A. et al. (2021) ‘Fecal microbiota transplant as a potential treatment for parkinson’s disease – a case series’, Clinical Neurology and Neurosurgery, 207, p. 106791. doi:10.1016/j.clineuro.2021.106791.
Kuai, X. et al. (2021) ‘Evaluation of fecal microbiota transplantation in parkinson’s disease patients with constipation’, Microbial Cell Factories, 20(1). doi:10.1186/s12934-021-01589-0.
Xue, L.-J. et al. (2020) ‘Fecal microbiota transplantation therapy for parkinson’s disease’, Medicine, 99(35). doi:10.1097/md.0000000000022035.
DuPont, H.L. et al. (2023) ‘Fecal microbiota transplantation in parkinson’s disease—a randomized repeat-dose, placebo-controlled clinical pilot study’, Frontiers in Neurology, 14. doi:10.3389/fneur.2023.1104759.
Cheng, Y. et al. (2023) ‘Efficacy of fecal microbiota transplantation in patients with parkinson’s disease: Clinical trial results from a randomized, placebo-controlled design’, Gut Microbes, 15(2). doi:10.1080/19490976.2023.2284247.
Bruggeman, A. et al. (2024) ‘Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate parkinson’s disease (gut-PARFECT): A double-blind, placebo-controlled, randomised, phase 2 trial’, eClinicalMedicine, 71, p. 102563. doi:10.1016/j.eclinm.2024.102563.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Marcin Dudek, Julia Silldorff, Małgorzata Zając, Tomasz Fura, Zuzanna Felińska, Stanisław Anczyk, Oliwia Iszczuk, Magdalena Gajkiewicz, Radosław Zaucha
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 90
Number of citations: 0